Global Infectious Disease Drug Market – Industry Trends and Forecast to 2031

Infectious Disease Drug Market Analysis and Size

The treatment of various infections is a primary application of the infectious disease drug market. These drugs target specific pathogens such as bacteria, viruses, fungi, and parasites to alleviate symptoms, cure infections, and prevent complications. They are crucial in managing a diverse array of infections, from common ailments such as respiratory and urinary tract infections to severe diseases such as HIV/AIDS, tuberculosis, malaria, and hepatitis. The market fosters continuous innovation through research and development efforts aimed at discovering new therapies, combating drug resistance, and improving treatment outcomes. Access to effective infectious disease drugs is vital for global health initiatives, helping to reduce morbidity, mortality, and healthcare costs associated with infectious diseases worldwide.

The global infectious disease drug market size was valued at USD 80.51 billion in 2023 and is projected to reach USD 123.08 billion by 2031, with a CAGR of 5.45% during the forecast period of 2024 to 2031.

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

An infectious disease drug is a medication designed to treat illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. These drugs work by targeting specific aspects of the infectious agent's lifecycle or by enhancing the body's immune response against the pathogen. They play a crucial role in controlling and curing various infectious diseases, ranging from common infections such as urinary tract infections to more severe illnesses such as tuberculosis and HIV/AIDS.

Infectious Disease Drug Market Dynamics

Drivers                                                                                          

• Increasing Advancements in Biotechnology

Advancements in biotechnology encompass breakthroughs in genomics, proteomics, and molecular biology, allowing for deeper insights into the mechanisms of infectious agents and host immune responses. Biotechnological tools enable the discovery of new drug targets, development of more precise diagnostic tests, and creation of novel therapeutic agents, including vaccines and antiviral drugs. Techniques such as CRISPR-Cas9 gene editing offer potential for targeted modifications in pathogens and host cells, enhancing treatment efficacy. Overall, biotechnological advancements accelerate the pace of drug discovery and development, addressing emerging infectious threats and improving patient outcomes in the infectious disease landscape.

For instance, Grifols' announcement underscores the impact of biotechnological advancements in enhancing treatments for infectious diseases. Yimmugo, an intravenous immunoglobulin therapeutic approved by the FDA for primary immunodeficiencies, exemplifies innovation in biotechnology and immunotherapy. This approval signifies progress in developing targeted therapies that bolster immune responses against infections, addressing both established and emerging infectious threats.

• Growing Government Initiatives

Governments worldwide allocate substantial funds to combat infectious diseases, including grants for pharmaceutical companies and research institutions. These initiatives aim to accelerate drug discovery, enhance surveillance systems for early detection of outbreaks, and strengthen healthcare infrastructure. Additionally, regulatory agencies collaborate with industry to streamline drug approval processes, ensuring timely availability of new treatments. Government-sponsored vaccination programs and public health campaigns also contribute to disease prevention, reducing the burden on healthcare systems and stimulating market growth for infectious disease drugs.

For instance, the FDA's active role in the COVID-19 pandemic, including issuing emergency use authorizations for diagnostic tests and providing guidance on test development, demonstrates its significant influence on the infectious disease drug market. These actions expedite access to essential tools for disease detection and management, thereby fostering rapid response capabilities and bolstering confidence in healthcare systems. Such regulatory support also encourages investment in infectious disease research and development, driving innovation and market growth in this critical healthcare sector.

Opportunities

• Increasing Healthcare Spending

As healthcare expenditures rise globally, there is greater investment in research, development, and distribution of drugs targeting infectious diseases. This financial commitment supports innovation in drug discovery, clinical trials, and regulatory approvals, leading to a broader range of effective therapies. Moreover, increased spending enables healthcare systems to upgrade infrastructure, improve diagnostic capabilities, and expand treatment options for infectious diseases. Ultimately, higher healthcare spending facilitates better patient outcomes, reduces disease burden, and supports ongoing efforts to combat infectious diseases worldwide.

• Rise in Re-Emerging Infections

Re-emerging infections refer to infectious diseases that were previously well-controlled or considered to be under decline but have resurged in prevalence or severity. These can be caused by various factors such as changes in pathogen virulence or drug resistance, environmental changes, urbanization, or global travel patterns. As these infections re-emerge, they create a heightened demand for new and improved infectious disease drugs to effectively treat and manage them. This drives pharmaceutical companies and researchers to innovate, develop new therapies, and repurpose existing drugs to combat these evolving pathogens. The re-emergence of infections thus acts as a significant driver of growth and investment in the infectious disease drug market.

Restraints/Challenges

• Global Health Inequalities

Disparities in healthcare access, infrastructure, and funding between developed and developing countries limit the distribution and uptake of new treatments. High costs of medications and lack of healthcare resources in poorer regions hinder market growth and profitability. Additionally, variations in regulatory standards and intellectual property rights can complicate market entry and distribution in different regions.

• High Development Costs

Developing new drugs involves extensive research, preclinical studies, and rigorous clinical trials to ensure safety and efficacy. The complexity of infectious diseases often requires specialized infrastructure and expertise, increasing operational expenses. Regulatory requirements further escalate costs, as stringent approvals are necessary to ensure public health safety. Additionally, the unpredictable nature of infectious diseases can lead to uncertain outcomes in drug development, making investment riskier for pharmaceutical companies. These high costs can deter investment in novel treatments, particularly for diseases with smaller patient populations or in regions with limited healthcare resources, thereby limiting innovation and access to new therapies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2022, May & Baker Nigeria Plc launched Artelum Combo, a novel malaria treatment combining Arthemeter Lumefantrine with Paracetamol. This innovative formulation aims to simplify malaria therapy by offering a complete treatment regimen in a single package. This launch addresses the urgent need for effective malaria treatments in Nigeria, where the disease remains a significant health concern
• In May 2021, Bajaj Healthcare launched Ivejaj, a new anti-parasitic drug approved by the Drugs Controller General of India for the treatment of COVID infections. Ivejaj represents a milestone in Bajaj Healthcare's efforts to combat COVID-19, providing a targeted therapeutic option to address parasitic aspects of the infection. This development underscores ongoing pharmaceutical innovations aimed at managing the global pandemic

Infectious Disease Drug Market Scope

The market is segmented on the basis of source type, disease type, treatment type, mode of action, drug type, route of administration and end-users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Source Type

• Bacterial Diseases
• Virusal Diseases
• Fungal Disease
• Parasitic Disease

Disease Type

• Jaundice
• Leprosy
• Listeria
• Lyme Disease
• Malaria
• Measles
• Molluscum Contagiosum
• Norovirus
• Pyelonephritis
• Rabies
• Severe Acute Respiratory Syndrome
• Sepsis
• Tetanus
• West Nile
• Zika
• Ebola Disease
• Others

Treatment Type

• Medication
• Dietary Supplements
• Surgery

Mode of Action Type

• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs
• Antiparasitic Drugs

Drug Type

• Tafenoquine
• Omadacycline
• Tecovirimat
• Eravacycline
• Delafloxacin
• Plazomicin
• Benznidazole
• Secnidazole
• Daclatasvir
• Dalbavancin
• Others

Route of Administration

• Oral
• Topical
• Intravenous

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Infectious Disease Drug Market Regional Analysis/Insights

The market is analysed and market size information is provided by country, type, drug, diagnosis, treatment and end-users as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Peru, Brazil, Argentina and Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA).

North America dominates the market due to a significant rise in the prevalence of infectious disorders, prompting increased demand for treatments. The favorable reimbursement scenario in the region facilitates accessibility to these treatments. Substantial growth in funding for research on infectious disease diagnostics enhances diagnostic capabilities. Lastly, heightened awareness about treatment options and technological advancements further contribute to North America's leadership in addressing infectious diseases. These factors collectively underscore the region's pivotal role in advancing healthcare solutions for infectious diseases.

Asia-Pacific region is expected for significant growth in the infectious disease drug market due to rising incidences of infectious diseases and increased healthcare spending on prevention and diagnosis. Factors such as urbanization, population growth, and changing lifestyles contribute to higher disease burdens. Governments and healthcare systems are increasingly prioritizing infectious disease control, driving demand for new treatments and diagnostics. Pharmaceutical companies are focusing on this region for expansion, drawn by its large and growing market potential in combating infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Infectious Disease Drug Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epigenetics diagnostic market.

Some of the major players operating in the market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Gilead Sciences, Inc. (U.S.)
• GlaxoSmithKline Plc (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Vertex Pharmaceuticals Incorporated (U.S.)
• ViiV Healthcare group of companies (U.K.)
• Sanofi S.A (France)
• Eli Lilly and Company (U.S.)
• Novartis AG (Switzerland)
• Mitsubishi Tanabe Pharma Corporation (Japan)

SKU-44741